Clinical Research Directory
Browse clinical research sites, groups, and studies.
Computational Assessment of GABA Receptor Modulation in PTSD
Sponsor: VA Office of Research and Development
Summary
A substantial majority of Veterans with posttraumatic stress disorder (PTSD) continue to suffer even with the best current medications. Progress in developing more effective medications is hampered by the substantial variability within Veterans with PTSD, meaning the most effective medication likely varies from individual to individual. New scientific tools to help identify distinct subgroups of Veterans with PTSD who are likely to respond to specific medications could help improve treatment in this population. Research has indicated that a specific subgroup of Veterans with PTSD with a high level of anxious arousal may benefit from medications which boost signaling of the neurotransmitter gamma-aminobutyric acid (GABA). This project aims to validate a clinical test to identify these individuals using new computational and neuroimaging methods combined with the medication lorazepam, a positive GABA modulator. The ultimate goal is to use these methods in future clinical trials of new medications to target the best treatments to individual Veterans with PTSD.
Official title: Individualized Computational Assessment of the Effects of GABA Receptor Modulation in Posttraumatic Stress Disorder
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
150
Start Date
2025-07-01
Completion Date
2029-06-30
Last Updated
2025-07-14
Healthy Volunteers
Yes
Conditions
Interventions
Lorazepam 1 mg tablet
Lorazepam is an oral medication which is FDA approved to treat anxiety.
Placebo tablet
Placebo will match the study drug in mode of administration, color, size, and taste.
Locations (1)
VA San Diego Healthcare System, San Diego, CA
San Diego, California, United States